AMDV Vaccine: Challenges and Perspectives.

Aleutian mink disease virus (AMDV) is known to cause the most significant disease in the mink industry. It is globally widespread and manifested as a deadly plasmacytosis and hyperglobulinemia. So far, measures to control the viral spread have been limited to manual serological testing for AMDV-positive mink. Further, due to the persistent nature of this virus, attempts to eradicate Aleutian disease (AD) have largely failed. Therefore, effective strategies to control the viral spread are of crucial importance for wildlife protection. One potentially key tool in the fight against this disease is by the immunization of mink against AMDV. Throughout many years, several researchers have tried to develop AMDV vaccines and demonstrated varying degrees of protection in mink by those vaccines. Despite these attempts, there are currently no vaccines available against AMDV, allowing the continuation of the spread of Aleutian disease. Herein, we summarize previous AMDV immunization attempts in mink as well as other preventative measures with the purpose to shed light on future studies designing such a potentially crucial preventative tool against Aleutian disease.

Breeding parameters on a mink farm infected with Aleutian mink disease virus following the use of methisoprinol.

Aleutian mink disease virus is one of the greatest threats to modern mink farming. The disease reduces fecundity and causes high mortality among kits. The aim of this study was to evaluate the effectiveness of methisoprinol in counteracting the effects of Aleutian disease, both by inhibiting replication of the virus and by mitigating the harmful effects of the disease on the fecundity and weight of infected animals. The study included 300 individuals with confirmed infection, divided according to antibody titres into three experimental groups, which received a 20% methisoprinol solution, and three control groups, which did not receive the immunostimulant. In the mink from the experimental groups, the number of copies of the genetic material of the virus in the spleens and lymph nodes was one order of magnitude lower than in the case of the control groups. Mink receiving the supplement also showed higher fecundity (on average 5.83 in the experimental groups and 4.83 in the control groups), and the weight of their offspring before slaughter was over 200 g higher. Given the lack of effective methods for immunoprophylaxis and treatment, methisoprinol supplementation can be an effective means of counteracting the effects of AMDV on persistently infected farms.

Construction and Immunogenicity Analysis of Whole-Gene Mutation DNA Vaccine of Aleutian Mink Virus Isolated Virulent Strain.

Aleutian mink disease (AD) is a chronic viral infection that causes autoimmune disorders in minks and presents a significant economic burden on mink farming. Despite the substantial challenges presented by AD, no effective vaccine is available and only partial protection has been achieved. We constructed a whole-gene nucleic acid vaccine from an isolated virulent Aleutian mink disease virus (ADV) strain (pcDNA3.1-ADV). Based on this whole-gene nucleic acid vaccine, we generated truncated mutant constructs by removing portions of the ADV VP2 gene using overlap extension polymerase chain reaction. pcDNA3.1-ADV-428 lacks nucleotides encoding VP2 amino acid residues 428-466, and pcDNA3.1-ADV-428-487 harbors additional deletion of nucleotides coding for VP2 amino acid residues 487-501. We also generated nucleic acid vaccines for the ADV NS1 gene, truncated ADV NS1 gene, ADV VS2 gene, and truncated ADV VS2 gene: pcDNA3.1-NS1, pcDNA3.1-NS1-D, pcDNA3.1-VP2, and pcDNA3.1-VP2-D, respectively. The immunogenicity of the seven DNA vaccines was confirmed by immunofluorescent evaluation. Sixty female minks were divided into 10 groups: seven groups were immunized with the DNA vaccines, one control group was injected with phosphate-buffered saline, one group was immunized with pcDNA3.1 empty vector, and one group was immunized with inactivated ADV-G virus. ADV antibody levels, percentage of CD8+ cells in blood, and levels of γ-globulin and circulating immune complexes in the serum were evaluated longitudinally over 36 weeks after ADV challenge. Minks that were immunized with the pcDNA3.1-ADV-428-487 nucleic acid vaccine produced ADV antibodies. After ADV challenge, the minks immunized with pcDNA3.1-ADV-428-487 nucleic acid vaccine had lower γ-globulin content and lower CIC in serum compared to other immunization groups. Although the pcDNA3.1-ADV-428-487 nucleic acid vaccine did not demonstrate complete protection against ADV, it demonstrated marked efficacy and could potentially be used as a vaccine to prevent losses in mink populations due to ADV. Discovery of effective means to vaccinate mink against ADV will not only improve overall health of mink populations but will also reduce the economic impact of ADV.

Prevalence of the Aleutian mink disease virus infection in Nova Scotia, Canada.

Despite many years of testing mink for serum antibodies against the Aleutian mink disease virus (AMDV) by counterimmunoelectrophoresis (CIEP) and elimination of reactors, this virus has remained the number one disease threat for the mink industry in Nova Scotia (NS). The objective of this study was to analyze CIEP test results to determine the success of the AMDV-control strategy in NS. A total of 2,964,920 CIEP test results from 82 ranches, spanning an eight-year period between 1998 and 2005, were analyzed. This survey included approximately 60% of the active ranchers in the province. The number of ranchers that tested their animals was 42 in 1998, gradually increased to 58 in 2003 and then showed some decline. The overall proportion of CIEP-positive mink was 3.34%, and varied between 5.22% in 1999 and 1.35% in 2005. The proportion of infected ranches ranged between 23.8% in 1998 and 70.7% in 2003. The overall trend was for a smaller proportion of infected animals but a larger proportion of infected ranches during this time period. Of the 82 ranches, 24 (29.3%) had negative CIEP in all tests, 15 (18.3%) had CIEP positive animals in every year tested, and 43 (52.4%) had positive and negative results in different years, indicating that AMDV infection was widespread in NS. There were 23 infected ranches with 8 years of uninterrupted testing. These ranchers performed 75.8% of the total samples tested (2,246,711), implying that they have diligently been trying to eradicate the virus. Infection persisted on three of these ranches for the entire 8 year period, and only two of the ranches remained CIEP negative for longer than four years. The average percentage of CIEP-positive mink on these ranches was 2.2, which was lower than 6.35% for the 33 infected ranches with occasional testing, and 73.6% and 82.4% for two ranches that had never used the CIEP test, showing that persistent test-and-removal strategy has been effective in reducing the prevalence of infected animals but has failed to eradicate the virus from most of the infected ranches.

A survey of Aleutian mink disease virus infection of feral American mink in Nova Scotia.

Spleen samples from 14 mink that were trapped in 4 counties of Nova Scotia were tested for the presence of the Aleutian mink disease virus (AMDV) by polymerase chain reaction. Viral DNA was not detected in samples from Kings County (n = 2), but was detected in all the mink sampled from Colchester (n = 2) and Halifax (n = 6) counties, and 3 of 4 mink from Yarmouth County. The high level of AMDV-infected mink in Colchester and Halifax counties may pose a serious threat to the captive mink and wild animal populations. Because treatment of infected free-ranging mink is not an option, AMDV control strategies for the captive mink should be primarily focused on bio-security to protect clean ranches.

DNA vaccination with the Aleutian mink disease virus NS1 gene confers partial protection against disease.

Aleutian disease virus (ADV) causes severe losses in mink. This happens in nature as well as in farms. In spite of several attempts to provide an efficient protective protein based vaccine, experiments have failed so far. Only partial protection has been obtained. The aim of this work was to construct and test a protective DNA vaccine based on the gene encoding for the ADV non-structural protein 1 (NS1) and to test this construct as a potential vaccine candidate against ADV infection or disease. First, the vaccine construct was tested by in vitro transfection studies. NS1 protein expression was found by immunofluorescent studies and the expected size of translated protein confirmed by Western blot. Then, 18 female mink were divided into three groups: a control group, a DNA vaccinated group, and a group which received DNA vaccine plus a boost with recombinant NS1 protein in the last immunization. After virus challenge, the two DNA vaccinated groups induced higher antibody levels in the first 23 weeks of the 32 week observation period. One month after virus challenge, the most interesting finding was, that the "DNA+protein" group exhibited a significantly higher percentage of CD8+ cells, when compared to the levels in the two other groups. This, we believe, indicate a memory CTL response created by the vaccination. Most CD8+ cells were found to contain interferon gamma as measured by FACS intracellular staining. Severity of Aleutian disease was judged by quantification of plasma gammaglobulin levels and mink death statistics. The findings let us to conclude, that the two DNA vaccinated groups of mink did show milder disease characteristics, but that the vaccine effect also in this trial could only be characterized as partial.

Melatonin reduces mortality from Aleutian disease in mink (Mustela vison).

Aleutian disease (AD) results from a persistent parvoviral infection that results in marked hypergammaglobulinemia and immune complex mediated lesions of the kidney, liver, lungs and, arteries. Melatonin protected both a wild type or demi strain and a demi/dark crossed strain of mink from AD. The biogenic amine also afforded protection against other non-diagnosed diseases naturally found on mink farms when it was available from a subcutaneously-placed reservoir. Some genetic strains of mink apparently differed in the resistance of mink to the virus and in the protective ability of melatonin. The demi strain was the most resistant followed by pastels, mahogany, darks, and those strains with the double recessive Aleutian gene. The protective action of melatonin appeared to result from melatonin's ability to scavenge free radicals, but it could also be due to the induction of antioxidant enzymes or to the modulation of immunity. Melatonin also protected mink against distemper.

Screening for antibodies against Aleutian disease virus (ADV) in mink. Elucidation of dubious results by additive counterimmunoelectrophoresis.

In order to distinguish true positive results in counterimmunoelectrophoresis from false positive ones an additive counterimmunoelectrophoresis was developed. The method was tested on selected mink serum samples as part of a routine testing for antibodies towards Aleutian disease virus on 3 million blood samples. The procedure of the method is, that a known positive serum sample is mixed with the patient serum to be tested. The result from a false positive sample will be one precipitin line towards virus and one nonspecific line. If the serum sample is a true positive one, the antibodies originating from the patient serum will be added to the antibodies in the standard positive serum giving only one precipitin line. The system is further extended by testing the serum samples towards an antigen preparation containing all the cellular components but free from virus.

Passive transfer of antiviral antibodies restricts replication of Aleutian mink disease parvovirus in vivo.

When mink kits were infected neonatally with a highly virulent strain of Aleutian disease virus (ADV), 100% of both Aleutian and non-Aleutian genotype mink died of interstitial pneumonia characterized by permissive ADV infection of alveolar type II cells. Treatment of infected kits with either mink anti-ADV gamma globulin or mouse monoclonal antibodies against ADV structural proteins reduced mortality by 50 to 75% and drastically reduced the severity of clinical signs. Interestingly, mink kits that survived the acute pulmonary disease all developed the chronic form of immune complex-mediated Aleutian disease. Thus, the antibodies directed against ADV structural proteins were capable of modulating the in vivo pathogenicity from an acute fulminant disease to a chronic immune complex-mediated disorder. The mechanism of this modulation was examined by strand-specific in situ hybridization. We found that the number of ADV-infected type II cells was the same in both untreated and antibody-treated kits. However, in the treated kits, viral replication and transcription were restricted at the cellular level. These data suggested that antibodies prevented acute viral pneumonia by restricting the intracellular level of viral replication and that the relevant antigenic determinants were contained within the viral structural proteins. The restricted levels of viral replication and transcription seen in antibody-treated mink kits resembled the levels observed in infected adult mink and suggested a role of antiviral antibodies in development of persistent infection and chronic immune complex disease.

Eradication of Aleutian disease of mink by eliminating positive counterimmunoelectrophoresis test reactors.

The counterimmunoelectrophorsis test was applied on three Aleutian disease virus-infected mink ranches for the detection of specific Aleutian disease virus antibody. All mink on the ranches were tested during the pelting season and before the breeding season for 4 consecutive years. Aleutian disease has been eliminated from the three commercial mink ranches by culling out all mink that were positive for Aleutian disease virus antibody.

Aleutian disease of mink. Prevention of lesions by immunosuppression.

Mink that were homozygous recessive for the Aleutian gene (aa) were inoculated with Aleutian disease virus (ADV) and simultaneously treated with cyclophosphamide (Cy). Control mink were inoculated with ADV. All mink were injected with bovine serum albumin (BSA) and their anti-BSA antibody response was measured to monitor the influence of drug therapy on the humoral antibody response. Formation of anti-BSA antibody was markedly suppressed and the hypergammaglobulinemia and development of AD lesions was inhibited in the Cy-treated mink. The non-Cy-treated control mink developed characteristic signs and lesions including glomerulonephritis and arteritis. The nontreated ADV-infected mink, but not the Cy-treated ADV-infected mink, had glomerular deposition of C3 and gamma globulin. Both groups had high titers of virus in their blood. These results indicate that the development of ADV lesions can be prevented by immunosuppressive treatment and further implicate host immune mechanisms in the pathogenesis of Aleutian disease.